Centaurus Financial Inc. Acquires 2,975 Shares of Eli Lilly and Company (NYSE:LLY)

Centaurus Financial Inc. grew its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 26.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,438 shares of the company's stock after buying an additional 2,975 shares during the quarter. Centaurus Financial Inc.'s holdings in Eli Lilly and Company were worth $11,146,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wealthedge Investment Advisors LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $2,379,000. Campbell Deegan Wealth Management LLC acquired a new position in shares of Eli Lilly and Company during the fourth quarter valued at $222,000. Lighthouse Financial LLC acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $3,351,000. Alpha Wealth Funds LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $477,000. Finally, IronOak Wealth LLC. bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth about $1,308,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $6.63 during trading hours on Wednesday, reaching $718.59. The company had a trading volume of 2,937,655 shares, compared to its average volume of 3,624,941. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The business has a fifty day simple moving average of $782.03 and a 200 day simple moving average of $801.29. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The firm has a market cap of $681.03 billion, a PE ratio of 61.37, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The company had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the previous year, the business earned $2.58 earnings per share. Eli Lilly and Company's revenue was up 45.2% on a year-over-year basis. On average, analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.83%. The ex-dividend date of this dividend is Friday, May 16th. Eli Lilly and Company's dividend payout ratio is 48.82%.

Analyst Ratings Changes

LLY has been the subject of a number of analyst reports. Cantor Fitzgerald initiated coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price objective for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Morgan Stanley reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Wall Street Zen upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research report on Friday, February 7th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.37.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.